Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages

  • Cancer Res. 2009 Dec 15;69(24):9395-403. doi: 10.1158/0008-5472.CAN-09-2050.
Amaya Puig-Kröger  1 ,  Elena Sierra-Filardi ,  Angeles Domínguez-Soto ,  Rafael Samaniego ,  María Teresa Corcuera ,  Fernando Gómez-Aguado ,  Manohar Ratnam ,  Paloma Sánchez-Mateos ,  Angel L Corbí
Affiliations
  • 1. Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Cientificas, Hospital General Universitario Gregorio Marañón, Madrid, Spain. [email protected]
Abstract

Macrophage activation comprises a continuum of functional states critically determined by cytokine microenvironment. Activated Macrophages have been functionally grouped according to their response to pro-Th1/proinflammatory stimuli [lipopolysaccharide, IFNgamma, granulocyte macrophage colony-stimulating factor (GM-CSF); M1] or pro-Th2/anti-inflammatory stimuli [interleukin (IL)-4, IL-10, M-CSF; M2]. We report that folate receptor beta (FRbeta), encoded by the FOLR2 gene, is a marker for Macrophages generated in the presence of M-CSF (M2), but not GM-CSF (M1), and whose expression correlates with increased folate uptake ability. The acquisition of folate uptake ability by Macrophages is promoted by M-CSF, maintained by IL-4, prevented by GM-CSF, and reduced by IFNgamma, indicating a link between FRbeta expression and M2 polarization. In agreement with in vitro data, FRbeta expression is detected in tumor-associated Macrophages (TAM), which exhibit an M2-like functional profile and exert potent immunosuppressive functions within the tumor environment. FRbeta is expressed, and mediates folate uptake, by CD163(+) CD68(+) CD14(+) IL-10-producing TAM, and its expression is induced by tumor-derived ascitic fluid and conditioned medium from fibroblasts and tumor cell lines in an M-CSF-dependent manner. These results establish FRbeta as a marker for M2 regulatory macrophage polarization and indicate that folate conjugates of therapeutic drugs are a potential immunotherapy tool to target TAM.